Neurologic Complications of Sickle Cell Disease

Piel F, Patil A, Howes R, Nyangiri O, Gething P, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–51. Ware R, de Montalembert M, Tshilolo L, Abboud M. Sickle cell disease. Lancet. 2017;390:311–23. Kauf T, Coates T, Huazhi L, Mody-Patel N, Hartzema A. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84:323–7. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–94. Steven A, Raghavan P, Rath T, Gandhi D. Neurologic and head and neck manifestations of sickle cell disease. Hematol Oncol Clin North Am. 2016;30:779–98. DeBaun M, Gordon M, McKinstry R, Noetzel M, White D, Sarnaik S, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. NEJM. 2014;371:699–710. • Lawrence C, Webb J. Sickle cell disease and stroke: diagnosis and management. Curr Neurol Neurosci Rep. 2016;16:27 The authors summarize review of acute and chronic management of stroke in sickle cell disease. Griessenauer C, Lebensburger J, Chua M, Fisher W, Hilliard L, Bemrich-Stolz C, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. 2015;16:64–73. DeBaun M, Kirkham F. Central nervous system complications and management in sickle cell disease. Blood. 2016;127:829–38. Parise L, Berliner N. Sickle cell disease: challenges and progress. Blood. 2016;127:789. Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2016;125:1653–61. Charneski L, Congdon H. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. Am J Health Syst Pharm. 2010;67:895–900. Nabavizadeh S, Vossough A, Ichord R, Kwiatkowski J, Pukenas B, Smith M, et al. Intracranial aneurysms in sickle cell anemia: clinical and imaging findings. J Neurointerv Surg. 2015;8:434–40. Solh Z, Taccone M, Marin S, Athale U, Breakey V. Neurological PRESentations in sickle cell patients are not always stroke: a review of posterior reversible encephalopathy syndrome in sickle cell disease. Pediatr Blood Cancer. 2016;63:983–9. Gaziev J, Marziali S, Paciaroni K, Isgrò A, di Giuliano F, Rossi G, et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23:1531–40. Alkan O, Kizilkilic E, Kizilkilic O, Yildirim T, Karaca S, Yeral M, et al. Cranial involvement in sickle cell disease. Eur J Radiol. 2010;76:151–6. Gibbs W, Opatowsky M, Burton E. AIRP best cases in radiologic-pathologic correlation: cerebral fat embolism syndrome in sickle cell β-thalassemia. Radiographics. 2012;32:1301–6. Oguz M, Aksungur E, Soyupak S, Yildirim A. Vein of Galen and sinus thrombosis with bilateral thalamic infarcts in sickle cell anaemia: CT follow-up and angiographic demonstration. Neuroradiology. 1994;36:155–6. Ciurea S, Thulborn K, Gowhari M. Dural venous sinus thrombosis in a patient with sickle cell disease: case report and literature review. Am J Hematol. 2006;81:290–3. Coutinho J. Cerebral venous thrombosis. J Thromb Haemost. 2015;13:S238–44. Venkataraman A, Adams R. Neurologic complications of sickle cell disease. Handb Clin Neurol. 2014;120:1015–25. Adams R, Nichols F, Figueroa R, McKie V, Lott T. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke. 1992;23:1073–7. Jordan L, Casella J, DeBaun M. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012;157:14–25. •• Mack A, Thompson A. Primary and Secondary stroke prevention in children with sickle cell disease. J Pediatr Health Care. 2017;31:145–54 Authors summarize review of silent cerebral ischemia and strokes their diagnostic criteria along with management. Arkuszewski M, Melhem E, Krejza J. Neuroimaging in assessment of risk of stroke in children with sickle cell disease. Adv Med Sci. 2010;55:115–29. Kassim A, Galadanci N, Pruthi S, DeBaun M. How I treat and manage strokes in sickle cell disease. Blood. 2015;125:3401–10. Chou S, Fasano R. Management of patients with sickle cell disease using transfusion therapy. Hematol Oncol Clin North Am. 2016;30:591–608. Adams R, Cox M, Ozark S, Kanter J, Schulte P, Xian Y, et al. Coexistent sickle cell disease has no impact on the safety or outcome of lytic therapy in acute ischemic stroke. Stroke. 2017;48:686–91. Powers W, Rabinstein A, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–e110. Adams R, McKie V, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. NEJM. 1998;339:5–11. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. NEJM. 2005;353:2769–78. Abboud M, Yim E, Musallam K, Adams R. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118:894–8. Ware R, Helms R. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119:3925–32. Ware R, Davis B, Schultz W, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2012;387:661–70. Bernaudin F, Verlhac S, Peffault de Latour R, Dalle JH, Brousse V, Petras E, et al. Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia. JAMA. 2019;321:266–76. Wang W, Ware R, Miller S, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663–72. Talano J, Cairo M. Hematopoietic stem cell transplantation for sickle cell disease: state of the science. Eur J Haematol. 2014;94:391–9. Kassim A, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017;10:259–66. Walters M, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–72. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110:2749–56. Smith E, McClain C, Heeney M, Scott R. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus. 2009;26:E10.